Zeta Global Q3 Non-GAAP Earnings, Revenue Rise; Lifts 2026 Guidance

MT newswire2026/11/09 20:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:26 PM EST, 11/09/2026 (MT Newswires) -- Zeta Global (ZETA) reported Q3 non-GAAP net income late Monday of $0.38 per share, up from $0.24 a year earlier. Analysts polled by FactSet expected $0.28. Revenue for the quarter ended Sept. 30 rose to $492.7 million from $337.2 million a year earlier. Analysts expected $471.1 million. The company now expects Q4 revenue of $521 million to $525 million, up $15 million at the midpoint from the prior guidance of $508 million. Analysts expect $510.4 million. Zeta raised full-year 2026 guidance to GAAP EPS of $0.22 to $0.24 from the prior forecast of $0.09 to $0.11, on revenue of $1.85 billion to $1.86 billion, up $37 million at the midpoint from the earlier projection of $1.82 billion. Analysts expect EPS of $0.11 on revenue of $1.82 billion.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12